What is the diagnosis and management for a patient with a Fine Needle Aspiration (FNA) result of the right thyroid showing thin colloid with rare clusters and single small follicular epithelial cells?

Bethesda Category II (Benign): Colloid Nodule

Your FNA result showing thin colloid with rare clusters and single small follicular epithelial cells is consistent with Bethesda Category II (Benign), most likely representing a benign colloid nodule or nodular goiter, and the recommended management is clinical and ultrasound surveillance rather than surgery. 1

Cytologic Interpretation

• Thin colloid with rare follicular cells is the classic cytologic pattern of a benign colloid nodule, which falls into Bethesda Category II with a malignancy risk of only 1-3% 1

• The presence of abundant colloid combined with sparse, regularly-spaced follicular epithelial cells strongly predicts a macrofollicular or mixed architectural pattern on histology, which is associated with benign disease 2

• This cytologic pattern (thin/watery colloid with scant follicular cells) has been validated as highly predictive of benign nodular goiter or colloid goiter in multiple studies 3, 4

Risk Stratification

• Bethesda II nodules carry an extremely low malignancy risk of 1-3%, which does not justify surgical intervention in the absence of compressive symptoms or highly suspicious clinical features 1

• The diagnostic accuracy of FNA for benign thyroid nodules approaches 95%, making this a highly reliable result 1

• False-negative rates for Bethesda II are only 1.5% when ultrasound features are concordant with benign cytology 1

Recommended Management Algorithm

Initial Approach

• Measure TSH levels to assess thyroid function and rule out autonomous nodule 1

• Perform high-resolution ultrasound to document baseline nodule characteristics and assess for any suspicious features that might be discordant with benign cytology 1

• Review ultrasound for high-risk features including microcalcifications, marked hypoechogenicity, irregular/infiltrative margins, absence of peripheral halo, or central hypervascularity 1

Surveillance Protocol

• Repeat ultrasound at 12-24 months to assess for interval growth or development of suspicious features 1

• Monitor for compressive symptoms including dysphagia, dyspnea, or voice changes 1

• Continue surveillance indefinitely if nodule remains stable and asymptomatic 1

Indications for Surgery (Despite Benign Cytology)

• Compressive symptoms clearly attributable to the nodule (dysphagia, dyspnea, voice changes) 1

• Cosmetic concerns that are significant and patient-driven 1

• Large nodules >4 cm due to increased false-negative rate and higher risk of compressive symptoms 1

• Discordance between benign cytology and highly suspicious ultrasound features (multiple high-risk features present) 1

Critical Pitfalls to Avoid

• Do not override benign cytology based solely on nodule size unless the nodule is >4 cm or causing compressive symptoms 1

• Do not perform molecular testing on Bethesda II nodules, as the pretest probability of malignancy is so low (1-3%) that molecular markers add minimal clinical value 1

• Do not proceed to surgery for Bethesda II nodules without specific indications, as this leads to overdiagnosis and overtreatment of benign disease 1

• Do not ignore worrisome clinical findings if present—false-negative results occur in up to 11-33% of cases when clinical suspicion is high 1

High-Risk Clinical Features That Would Modify Management

If any of the following are present, consider repeat FNA or closer surveillance despite benign cytology:

• History of head and neck irradiation (increases malignancy risk 7-fold) 1

• Family history of thyroid cancer, particularly medullary carcinoma or familial syndromes 1

• Age <15 years or male gender (higher baseline malignancy probability) 1

• Rapidly growing nodule over serial ultrasounds 1

• Firm, fixed nodule on palpation suggesting extrathyroidal extension 1

• Suspicious cervical lymphadenopathy on ultrasound 1

• Vocal cord paralysis suggesting invasive disease 1

Role of Repeat FNA

• Repeat FNA is generally not indicated for Bethesda II nodules unless there is significant interval growth (>20% increase in two dimensions with minimum 2mm increase) or development of new suspicious ultrasound features 1

• If repeat FNA is performed due to discordant features, ensure ultrasound guidance to sample any suspicious solid components 1